
City Therapeutics Inc.
CTY | NASDAQ
$20.74
+$0.03 (+0.14%)
Nov 2, 2026, 3:59 PM ET · Market open
TTM Period Ending | Q2 2020 Jun 30, 2020 | Q1 2020 Mar 31, 2020 | Q4 2019 Dec 31, 2019 | Q3 2019 Sep 30, 2019 | Q2 2019 Jun 30, 2019 | Q1 2019 Mar 31, 2019 | Q4 2018 Dec 31, 2018 | Q3 2018 Sep 30, 2018 | Q2 2018 Jun 30, 2018 | Q1 2018 Mar 31, 2018 | Q4 2017 Dec 31, 2017 | Q3 2017 Sep 30, 2017 | Q2 2017 Jun 30, 2017 | Q1 2017 Mar 31, 2017 | Q4 2016 Dec 31, 2016 | Q3 2016 Sep 30, 2016 | Q2 2016 Jun 30, 2016 | Q1 2016 Mar 31, 2016 | Q4 2015 Dec 31, 2015 | Q3 2015 Sep 30, 2015 | Q2 2015 Jun 30, 2015 | Q1 2015 Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 6.49B | 8.02B | 8.16B | 8.26B | 8.37B | 8.42B | 8.49B | 8.49B | 8.49B | 8.52B | 8.55B | 8.64B | 8.73B | 8.82B | 8.91B | 8.94B | 9B | 9B | 8.96B | 8.95B | 8.86B | 8.84B |
Cost of Revenue | 2.21B | 2.3B | 2.44B | 2.49B | 2.55B | 2.67B | 2.77B | 2.8B | 2.85B | 2.87B | 2.88B | 2.92B | 2.94B | 2.95B | 2.93B | 2.9B | 2.88B | 2.89B | 2.87B | 2.95B | 2.92B | 2.87B |
Gross Profit | 4.29B | 5.72B | 5.72B | 5.77B | 5.82B | 5.75B | 5.73B | 5.69B | 5.64B | 5.65B | 5.67B | 5.72B | 5.79B | 5.87B | 5.98B | 6.04B | 6.13B | 6.11B | 6.09B | 6B | 5.94B | 5.97B |
Operating Income | 2.83B | 2.9B | 2.88B | 2.94B | 2.91B | 2.79B | 2.66B | 2.58B | 2.42B | 2.37B | 2.31B | 2.23B | 2.25B | 2.28B | 2.32B | 2.43B | 2.42B | 2.34B | 2.26B | 2.13B | 2.09B | 2.12B |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 2.43B | 2.49B | 2.47B | 2.52B | 2.44B | 2.31B | 2.16B | 2.05B | 1.92B | 1.85B | 1.79B | 1.71B | 1.69B | 1.72B | 1.76B | 1.86B | 1.89B | 1.81B | 1.73B | 1.62B | 1.58B | 1.61B |
Net Income | 1.8B | 1.84B | 1.83B | 1.85B | 1.82B | 1.77B | 1.67B | 2.11B | 1.92B | 1.76B | 1.66B | 1.05B | 1.04B | 1.06B | 1.09B | 1.17B | 1.18B | 1.13B | 1.07B | 969M | 946M | 964M |
Selling & General & Admin | -1.66B | -493M | 659M | 5.32B | 5.46B | 5.63B | 5.83B | 5.92B | 6.07B | 6.15B | 6.24B | 6.41B | 6.48B | 6.54B | 6.59B | 6.52B | 6.58B | 6.66B | 6.7B | 6.82B | 6.77B | 6.73B |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | -1.66B | -493M | 659M | 5.32B | 5.46B | 5.63B | 5.83B | 5.92B | 6.07B | 6.15B | 6.24B | 6.41B | 6.48B | 6.54B | 6.59B | 6.52B | 6.58B | 6.66B | 6.7B | 6.82B | 6.77B | 6.73B |
Interest Expense | -191M | -95M | n/a | 384M | 401M | 425M | 448M | 467M | 472M | 469M | 465M | 464M | 468M | 471M | 478M | 479M | 477M | 476M | 473M | 473M | 469M | 466M |
Selling & Marketing Expenses | 1.16B | 2.3B | 3.44B | 4.67B | 4.77B | 4.89B | 5.03B | 5.1B | 5.19B | 5.26B | 5.31B | 5.4B | 5.47B | 5.53B | 5.57B | 5.58B | 5.61B | 5.67B | 5.69B | 5.77B | 5.72B | 5.66B |
Cost & Expenses | 5.57B | 6.34B | 7.1B | 7.8B | 8.01B | 8.3B | 8.6B | 8.72B | 8.92B | 9.02B | 9.12B | 9.34B | 9.42B | 9.49B | 9.52B | 9.41B | 9.46B | 9.55B | 9.58B | 9.77B | 9.69B | 9.6B |
Income Tax Expense | 633M | 647M | 641M | 676M | 621M | 535M | 494M | -56M | 1M | 90M | 134M | 664M | 655M | 664M | 678M | 695M | 707M | 680M | 659M | 651M | 636M | 646M |
Shares Outstanding (Basic) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Diluted) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EPS (Basic) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EPS (Diluted) | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA | 3.58B | 3.75B | 3.83B | 4.28B | 4.23B | 4.15B | 4.04B | 4B | 3.91B | 3.87B | 3.84B | 3.78B | 3.79B | 3.85B | 3.92B | 4.06B | 4.13B | 4.09B | 4.05B | 3.97B | 3.96B | 4.01B |
EBIT | 975M | 1.72B | 2.47B | 2.91B | 2.84B | 2.73B | 2.61B | 2.52B | 2.39B | 2.32B | 2.26B | 2.18B | 2.16B | 2.19B | 2.24B | 2.34B | 2.37B | 2.29B | 2.21B | 2.09B | 2.05B | 2.08B |
Depreciation & Amortization | 1.35B | 1.36B | 1.36B | 1.37B | 1.39B | 1.41B | 1.44B | 1.48B | 1.52B | 1.55B | 1.58B | 1.6B | 1.63B | 1.65B | 1.68B | 1.72B | 1.76B | 1.8B | 1.84B | 1.88B | 1.91B | 1.94B |
Add to Watchlist
Select watchlists to add or remove CTY